Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies

Open Forum Infectious Diseases

Volumn 1, Issue 2, 2014, Pages

  Soriano, Melinda M ^a,b   Danziger, Larry H ^a   Gerding, Dale N ^c,d   Johnson, Stuart ^c,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RESURRECTION MEDICAL CENTER   (United States)

^c HINES VA HOSPITAL   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Clostridium difficile infection; Fidaxomicin; Recurrence

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE FREE INTERVAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; VERY ELDERLY;

EID: 84952789314     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu069     Document Type: Article

References (23)

1. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324-33.
2. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
3. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386-8.
4. Bakken JS, Polgreen PM, Beekmann SE, et al. Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (rCDI) among infectious disease physicians. Anaerobe 2013; 24:20-4.
5. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44:846-8.
6. Johnson S, Schriever C, Patel U, et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009; 15:290-1.
7. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66:2850-5.
8. Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59:705-10.
9. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
10. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
11. Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55(Suppl 2):S154-61.
12. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
13. Bono BR, Culshaw DL, Mitropoulos IF, et al. Patients with recalcitrant Clostridium difficile-associated diarrhea treated successfully with fidaxomicin: a case series. Infect Dis Clin Pract 2014; doi:10.1097/ IPC.0b013e31829ff59b.
14. Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridiumdifficile infection in a child. J Antimicrob Chemother 2013; 68:1688-9.
15. Orenstein R. Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing. Clin Infect Dis 2012; 55:613-4.
16. Johnson S, Gerding DN. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 2013; 56:309-10.
17. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435-8.
18. Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One 2013; 8:e76269.
19. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012; 20:313-9.
20. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55(Suppl 2):S132-42.
21. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156(Pt 11):3354-9.
22. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440-7.
23. Johnson S, Adelmann A, Clabots CR, et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159:340-3.